Fulcrum Therapeutics, Inc.
Financials
Valuation Metrics
Fulcrum Therapeutics, Inc.'s Market Cap is $287M. At end of 2025 it was $717M. Ranked #2954 of 3,121 in US market (top 95%), #1335 of 1,463 on NASDAQ (top 91%), #245 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $287M | US#2,954/3,121 Sec#245/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-85M | US—/3,121 Sec—/266 |
| Total Assets | $324M | US#2,901/3,121 Sec#205/266 |
| Net Assets | $311M | US#2,508/3,121 Sec#158/266 |
| Employees | 9 | US#2,789/3,121 Sec#225/266 |
| Value | ||
| P/B | 0.92x | US#308/3,121 Sec#9/266 |
| FCF Yield | -23.06% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -27.36% | US#2,548/3,121 Sec#109/266 |
| ROA | -26.24% | US#2,862/3,121 Sec#148/266 |
| Financial Health | ||
| Debt Ratio | 4.27% | US#34/3,121 Sec#10/266 |
| Total Debt | $5M | US#2,903/3,121 Sec#216/266 |
| FCF | $-66M | US#2,563/3,121 Sec#121/266 |
| Cash | $48M | US#2,588/3,121 Sec#229/266 |
| Current Ratio | 31.35x | US#82/3,121 Sec#10/266 |
| Performance | ||
| 1Y Return | -50.13% | US#2,902/3,121 Sec#244/266 |
| 1M Return | -3.84% | US#1,317/3,121 Sec#121/266 |
| From 52W High | -76.11% | US#3,054/3,121 Sec#252/266 |
| 1Y MDD | -78.49% | US#3,055/3,121 Sec#253/266 |
| Trading | ||
| Volume | 2,688,816 shares | US#1,501/3,121 Sec#163/266 |
| Trading Value | $10M | US#2,786/3,121 Sec#236/266 |
| Per Share | ||
| EPS | $-1.11 | US—/3,121 Sec—/266 |
| BPS | $4.07 | US#2,357/3,121 Sec#139/266 |
Company Info
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.